On October 15, 2020, Microkhim Research and Production Company submitted to the State Expert Center at the Ministry of Health of Ukraine documents for registration of Favipiravir-Microkhim, the first Ukrainian generic of the Japanese antiviral drug Avigan (favipiravir). At the beginning of the year, this drug was included in the domestic protocol for the treatment of the disease caused by COVID-19, at the same time, it is not registered in Ukraine, so it was almost impossible to buy it.
Recall that in September, Japanese researchers in clinical trials received evidence of the effectiveness of the use of “Avigan” (favipiravir) for the treatment of disease caused by coronavirus infection. Previously, this drug has been used successfully during the swine flu epidemic. It is believed that it not only eliminates the clinical manifestations of the disease, but, above all, affects the pathogenesis of the coronavirus in humans. At the same time, back in April in Ukraine, the original drug was included in the list of drugs to prevent the spread of coronavirus disease, which were exempt from import duties and VAT.
“Back in April, we announced the start of work in this direction. And today we report: we did it. “Microkhim” has developed the first domestic generic drug, which, according to the results of research, affects the pathogenesis of coronavirus. Its name is “Favipiravir – Microkhim”. In the near future, it will undergo control studies in an authorized laboratory on the basis of the State Expert Center at the Ministry of Health, after which the conditions and terms of clinical trials (bioequivalence) will be set. Given the importance of this issue in terms of increasing the dynamics of the spread of COVID-19 in Ukraine, we hope for the prompt passage of regulatory procedures, “- said CEO of” Microkhim” Igor Pogromsky.
At the same time, in early October 2020, the Cabinet of Ministers of Ukraine approved a draft agreement between the governments of Ukraine and Japan on the transfer of humanitarian aid to our country in the form of a batch of the drug “Favipiravir”. At the same time, it is unlikely that the humanitarian party will be able to cover the needs of Ukrainians in the long-term drug against coronavirus. However, the entry of the domestic drug from Microkhim into the Ukrainian market will not only solve the problem of supplying the necessary volumes of Faviparavir in a pandemic, but also provide a much lower pricing policy for the population than in the case of the original drug.